Lymphomas

Copiktra Approved for Relapsed/Refractory CLL/SLL, Follicular Lymphoma

By September 25, 2018

In a clinical trial involving patients with CLL (N=312) or SLL (N=7), median progression-free survival (PFS) was 16.4 months for patients treated with duvelisib vs 9.1 months for those treated with ofatumumab.

Duvelisib NDA Gets Priority Review for Relapsed/Refractory CLL/SLL, Follicular Lymphoma

By April 09, 2018

Duvelisib is a first-in-class oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma.

Calquence Gets Accelerated Approval for Mantle Cell Lymphoma

By October 31, 2017

Acalabrutinib is a small-molecule inhibitor of BTK.

FDA Approves Gene Therapy for Certain Types of Non-Hodgkin Lymphoma

By October 19, 2017

Yescarta, a CD19-directed genetically modified autologous T cell immunotherapy, is indicated for use in large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Priority Review Granted for Axicabtagene Ciloleucal in NHL

By May 26, 2017

In the ZUMA-1 trial 42% of patients demonstrated ongoing response at the 8.7-month follow-up, of which 39% achieved complete response.

Exercise Important for Men After Cancer Diagnosis

January 28, 2014

Men who are physically active after a cancer diagnosis have significantly improved survival.